Company: GNMSF
Filing Date: 2025-09-29
Form Type: SC TO-C
Source: 0000947871-25-000868
Chunk: 3

Company: GENMAB A/S
Filing Date: 2025-09-29
Form: SC TO-C
Chunk 3
---
 materially from any
future results or performance expressed or implied by such statements. The important factors that could cause our actual results or
performance to differ materially include, among others, the occurrence of any event, change or other circumstance that could give
rise to the right of Genmab or the Company or both of them to terminate the transaction agreement, including circumstances requiring
a party to pay the other party a termination fee pursuant to the transaction agreement; the failure to obtain applicable regulatory
approvals or clearances or the Company shareholder approval in a timely manner or otherwise; the risk that the proposed transaction
may not close in the anticipated timeframe or at all due to one or more of the other closing conditions to the proposed transaction
not being satisfied or waived; the risk that there may be unexpected costs, charges or expenses resulting from the proposed
transaction; risks related to the ability of Genmab to successfully integrate the Company’s business with Genmab’s
existing businesses and achieve the expected benefits of the proposed transaction within the expected timeframes or at all and the
possibility that such integration may be more difficult, time consuming or costly than expected; risks that the proposed transaction
disrupts Genmab’s or the Company’s current plans and operations; risks related to disruption of each company’s
management’s time and attention from ongoing business operations due to the proposed transaction; continued availability of
capital and financing and rating agency actions; the risk that any announcements relating to the proposed transaction could have
adverse effects on the market price of Genmab’s and/or the Company’s securities or operating results; the risk that the
proposed transaction and its announcement could have an adverse effect on the ability of Genmab and the Company to retain and hire
key personnel, and to maintain relationships with their respective business partners and on their respective operating results and
businesses generally; risks typically associated with conducting clinical trials, including the risk that additional clinical trials
testing the Company’s products may not be successful; the risk that the Company’s products may not be approved on
expected timelines or at all; the risk of litigation that could be instituted against Genmab or its directors, managers or officers
and/or regulatory actions related to the proposed transaction, including the effects of any outcomes related thereto; risks related
to unpredictable and severe or catastrophic events, including but not limited to acts of terrorism, war or hostilities,
cyber-attacks, or the impact of any pandemic, epidemic or outbreak of an infectious disease in the United